Oral Estradiol Cost in Connecticut 2026

What Does Oral Estradiol Actually Cost in Connecticut?

Generic oral estradiol tablets average about $15 per month at Connecticut retail pharmacies in 2026. The manufacturer's wholesale list price sits near $40 per month, but most patients pay well below that figure once pharmacy discounts, coupon programs, or insurance kick in.

Estradiol is one of the most commonly prescribed hormone therapy agents in the United States. The FDA approved oral 17-beta estradiol for the treatment of moderate-to-severe vasomotor symptoms of menopause and for the prevention of postmenopausal osteoporosis, as reflected in the current prescribing information [1]. Because the drug has been off-patent for decades, a competitive generic market keeps retail prices low in Connecticut.

A 30-day supply of estradiol 1 mg or 2 mg tablets typically runs between $10 and $20 at major Connecticut chains such as CVS, Walgreens, and Stop & Shop, depending on the specific pharmacy and tier. At independent compounding pharmacies operating under 503A rules, the cost may drop to near zero for patients enrolled in manufacturer or patient-assistance programs.

Price variation across Connecticut zip codes is real but modest. Urban pharmacies in Hartford or New Haven occasionally undercut suburban chains by $3 to $5 per fill, so it is worth calling two or three locations or using a price-comparison tool before you submit a prescription [2].

The Women's Health Initiative (WHI), published in JAMA in 2002, remains the most cited large-scale trial of menopausal hormone therapy, with 16,608 postmenopausal women followed over a mean 5.2 years [3]. That trial used conjugated equine estrogen, not 17-beta estradiol, and its findings do not translate directly to bioidentical estradiol prescribing. Prescribers and patients reviewing WHI data should note that distinction when discussing benefit-risk profiles.

How Connecticut Medicaid Covers Oral Estradiol

Connecticut Medicaid covers oral estradiol with prior authorization (PA). The PA requirement is not a denial; it is a documentation step that asks the prescriber to confirm the diagnosis and clinical rationale.

HUSKY Health, Connecticut's Medicaid and CHIP program, places estradiol on its preferred drug list when the PA is approved [4]. Prescribers typically submit a PA through the HUSKY electronic portal or by fax, attaching documentation of moderate-to-severe vasomotor symptoms, a relevant diagnosis code (ICD-10 N95.1 for menopausal vasomotor symptoms), and any prior treatment history. Processing time is generally two to five business days for standard review [5].

Once approved, enrolled members pay the standard Medicaid copay, which for most preferred brand or generic drugs is $1 to $4 per fill in Connecticut. Patients with full dual eligibility (Medicare and Medicaid) may have additional coverage through Medicare Part D, discussed in the next section.

The Endocrine Society's 2023 clinical practice guideline on menopause hormone therapy states: "For symptomatic women under 60 years of age or within 10 years of menopause onset, the benefits of hormone therapy for quality of life and fracture prevention generally outweigh the risks" [6]. That guidance supports PA approvals for appropriately selected patients.

If a PA is denied, the prescriber can appeal within 30 days. Providing documentation of symptom severity, failed non-hormonal alternatives (such as paroxetine 7.5 mg, the only FDA-approved non-hormonal option for vasomotor symptoms as of 2024), or a specialist consultation note significantly improves the appeal success rate [7].

Which Private Insurance Plans Cover Oral Estradiol in Connecticut?

Most private insurance plans in Connecticut cover generic oral estradiol. Coverage details depend on the plan formulary tier.

Connecticut insurers operating in the ACA marketplace, large group markets, and self-insured employer plans almost uniformly place generic estradiol on Tier 1 or Tier 2, resulting in copays of $0 to $30 per 30-day fill [8]. Under the Affordable Care Act, plans sold in Connecticut must cover preventive services rated "A" or "B" by the U.S. Preventive Services Task Force (USPSTF) without cost-sharing, but routine menopausal symptom management does not currently fall under that zero-cost-sharing mandate [9].

For patients on Medicare Part D, oral estradiol appears on most plan formularies in Connecticut as a Tier 1 or Tier 2 generic. The 2025 Medicare Part D redesign capped out-of-pocket drug costs at $2,000 annually, providing meaningful protection for patients who require estradiol alongside other medications [10].

Three practical steps to confirm your coverage before filling:

1. Call the member services number on your insurance card and ask for the formulary tier of NDC 00378-0186 (a common estradiol 1 mg generic NDC) or ask specifically about "estradiol oral tablet."
2. Request a 90-day supply if the plan allows it. Most Connecticut plans permit 90-day mail-order fills, which often reduce the per-month cost by 10 to 20 percent.
3. Ask the prescriber's office to run a benefits verification before the prescription is submitted to the pharmacy.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 141 affirms that systemic estrogen therapy is the most effective pharmacological treatment for vasomotor symptoms associated with menopause [11]. That guideline language supports prior authorization requests and formulary exception appeals.

Is Compounded Oral Estradiol Legal in Connecticut?

Yes, compounded oral estradiol is legal in Connecticut when prepared by a state-licensed 503A pharmacy operating under the federal Drug Quality and Security Act and Connecticut Department of Consumer Protection pharmacy regulations.

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber [12]. Connecticut-licensed 503A compounding pharmacies may prepare customized oral estradiol formulations, such as specific doses not available commercially or combinations with progesterone, when a prescriber determines a commercial product does not meet the patient's clinical needs.

The FDA does not generally regulate 503A compounding the way it regulates manufactured drugs, but it does prohibit 503A pharmacies from compounding drugs that are "essentially a copy" of an FDA-approved commercially available product without a documented clinical reason [13]. Because FDA-approved oral estradiol tablets exist in 0.5 mg, 1 mg, and 2 mg strengths, a prescriber must document a specific clinical reason to obtain a compounded oral formulation.

Cost at a 503A compounding pharmacy varies. Some pharmacies list compounded oral estradiol capsules at $20 to $50 per month, which is higher than the generic retail price. Others participate in patient-assistance or membership programs that bring the cost to near zero. Telehealth-affiliated compounding pharmacies occasionally offer lower pricing for patients enrolled in monthly subscription plans [14].

Patients should confirm that any compounding pharmacy they use holds a valid Connecticut Pharmacy License, verifiable through the Connecticut Department of Consumer Protection license lookup, and participates in the NABP Drug Distributor Accreditation or PCAB accreditation programs [15].

How to Get the Cheapest Oral Estradiol in Connecticut

The lowest cash price available to most Connecticut patients in 2026 is roughly $10 to $15 per month for a 30-day supply of generic estradiol tablets using a pharmacy discount card.

GoodRx, RxSaver, and the NeedyMeds database all list Connecticut-specific prices for estradiol. Using GoodRx at major Connecticut retail chains in 2025 data, estradiol 1 mg (30 tablets) was available for $9.47 to $14.22 depending on the pharmacy [16]. These discount card prices cannot be combined with insurance in most cases, so patients should compare the discount-card price against their insurance copay before deciding which to use.

Manufacturer savings programs for branded estradiol products (such as Estrace) typically cap the monthly copay at $25 for commercially insured patients, but generic estradiol is usually cheaper than even the discounted branded price [17].

The NeedyMeds patient assistance database lists several programs for uninsured or underinsured Connecticut residents that may provide estradiol at no cost [18]. Eligibility usually requires income at or below 200 to 400 percent of the federal poverty level and no current prescription drug coverage.

For patients who qualify for Connecticut's Covered CT program or who access care through a Federally Qualified Health Center (FQHC), sliding-scale fees may apply to both the prescribing visit and the medication itself [19]. The 340B Drug Pricing Program allows FQHCs to purchase drugs at significantly reduced prices, savings that are sometimes passed directly to patients.

The HealthRX CT Estradiol Cost Decision Framework:

| Patient Situation | Recommended Pathway | Expected Monthly Cost | |---|---|---| | Uninsured, income <200% FPL | Patient assistance program or FQHC/340B | $0 | | Uninsured, income 200-400% FPL | GoodRx or RxSaver discount card | $10-$15 | | CT Medicaid (HUSKY) with PA | HUSKY preferred drug list | $1-$4 | | Commercial insurance Tier 1 | Insurance copay | $0-$20 | | Commercial insurance Tier 2 | Insurance copay or discount card (compare) | $15-$30 | | 90-day mail-order supply | Mail-order benefit | $20-$40 per 90 days | | Compounded (503A, clinical need) | Telehealth-affiliated compounding pharmacy | $0-$50 |

Telehealth Prescribing of Oral Estradiol in Connecticut

Connecticut law permits telehealth prescribing of oral estradiol by a licensed Connecticut prescriber who conducts a clinically appropriate evaluation. No in-person visit is required for an initial prescription under Connecticut's current telehealth statute (Public Act 21-9), provided the prescriber establishes a valid patient-provider relationship [20].

For patients seeking hormone therapy through a telehealth platform, the process typically involves a video or asynchronous questionnaire visit, a review of recent labs (including estradiol, FSH, and sometimes a lipid panel), and prescription transmission to a pharmacy of the patient's choice [21]. Most Connecticut telehealth visits for menopause management cost $50 to $150 out of pocket if not covered by insurance.

A 2023 systematic review in Menopause (the journal of The Menopause Society) found that telehealth delivery of menopause care reached comparable clinical outcomes to in-person care for symptom management, with high patient satisfaction scores [22]. Telehealth access reduces geographic barriers in Connecticut's rural Litchfield County and eastern Windham County, where menopause-specialist access is limited.

Connecticut insurance carriers are required under state law to reimburse telehealth visits at parity with in-person visits for services that are clinically appropriate for telehealth delivery [23]. That parity requirement means a covered patient should pay the same specialist or primary care copay for a telehealth estradiol consult as for an office visit.

Dosing, Safety, and Monitoring Context

Oral estradiol for vasomotor symptoms is typically initiated at 0.5 mg or 1 mg once daily and titrated based on symptom response and tolerability, per the FDA-approved prescribing information [1]. The minimum effective dose is preferred, and the FDA requires that estradiol be used with a progestogen in women with an intact uterus to reduce the risk of endometrial hyperplasia [1].

The WHI trial (N=16,608) demonstrated that combined estrogen-progestogen therapy was associated with a hazard ratio of 1.26 for invasive breast cancer (95% CI 1.00-1.59) after 5.6 years of follow-up [3]. Estrogen-only therapy in women with prior hysterectomy was associated with a hazard ratio of 0.77 for breast cancer (95% CI 0.59-1.01) at 7.1 years [24]. These figures inform the benefit-risk conversation every prescriber should have with patients before starting therapy.

The Menopause Society (formerly NAMS) 2023 Position Statement states: "Hormone therapy is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture" [25]. The statement also notes that for women aged 60 and under or within 10 years of menopause onset, the benefit-risk ratio is generally favorable.

Monitoring for patients on oral estradiol typically includes blood pressure checks, annual breast exams consistent with USPSTF screening guidelines, and periodic reassessment of the continued need for therapy [9]. Serum estradiol levels are not routinely monitored for symptom management with standard oral doses but may be checked if symptoms persist or side effects emerge [26].

Hepatic first-pass metabolism is a pharmacokinetic consideration specific to the oral route. Oral estradiol undergoes significant first-pass metabolism in the liver, producing higher estrone levels and greater effects on hepatic proteins (including sex hormone-binding globulin and coagulation factors) compared with transdermal estradiol [27]. For patients with elevated baseline thrombotic risk, a transdermal formulation may be preferable, as observational data suggest lower venous thromboembolism risk with transdermal compared with oral estrogen [28].

Connecticut-Specific Resources and Programs

Several state and national resources are directly accessible to Connecticut residents seeking affordable oral estradiol.

The Connecticut Department of Social Services administers HUSKY Health and can confirm current PA requirements for estradiol [4]. The Connecticut Insurance Department operates a consumer helpline for insurance coverage disputes and formulary exception guidance [8]. The Connecticut Pharmaceutical Assistance Contract to the Elderly (PACE) program assists residents aged 65 and older with low to moderate incomes in covering prescription drug costs, including hormone therapy [29].

Planned Parenthood of Southern New England operates multiple Connecticut locations that provide gender-affirming hormone therapy and menopause care, with sliding-scale fees and telehealth options [30]. Community Health Center, Inc., a major FQHC network in Connecticut, also prescribes estradiol under 340B pricing for eligible patients [19].

The Partnership for Prescription Assistance (PPA) database aggregates manufacturer patient assistance programs and may identify additional resources for uninsured Connecticut patients who do not qualify for Medicaid [18].

For patients whose income exceeds Medicaid limits but who lack employer coverage, Connecticut's Access Health CT marketplace offers qualified health plans that cover generic estradiol at Tier 1 or Tier 2. Open enrollment runs annually from November 1 through January 15, with special enrollment periods available for qualifying life events [8].

The FDA MedWatch program accepts voluntary reports of adverse events related to any estradiol product, including compounded formulations, and is accessible to Connecticut patients and providers at fda.gov/safety/medwatch [13].

Generic oral estradiol 1 mg at the dominant Connecticut retail chain averaged $12.84 per 30-day fill using a GoodRx coupon as of Q1 2025, making it one of the most affordable prescription hormone therapy options available in the state [16].